Almirall's Lebrikizumab Shows Sustained Efficacy in Long-Term Atopic Dermatitis Study

Event summary

  • Almirall presented interim results from the Phase 3b ADlong study showing lebrikizumab maintained near-complete skin clearance and itch relief for up to four years in moderate-to-severe atopic dermatitis patients.
  • 77% of patients were on lebrikizumab monotherapy, and 80% achieved results without topical corticosteroids.
  • The study reported 94% EASI-75, 75% EASI-90, 68% IGA 0,1, and 78% Pruritus NRS ≤4 at week 48.
  • No new safety signals were observed, with most adverse events being mild or moderate.

The big picture

Almirall's long-term data for lebrikizumab reinforces its position in the competitive atopic dermatitis market, where sustained efficacy and safety are critical differentiators. The results come as biopharmaceutical companies increasingly focus on targeted biologics to address chronic inflammatory skin conditions. With Eli Lilly retaining rights outside Europe, the strategic partnership dynamics will also shape lebrikizumab's global reach.

What we're watching

Regulatory Approvals
Whether the sustained efficacy data will support expanded regulatory approvals for lebrikizumab beyond its current indications.
Market Competition
How Almirall will position lebrikizumab against emerging therapies in the atopic dermatitis space.
Commercial Strategy
The pace at which Almirall can scale lebrikizumab's commercialization in Europe and other regions.